45K likes, — supercarsfor.sale on October 11, 2024: ‘The new Tesla Robovan. What do you think? Video by @dragtimescom’
Ready to set another industry record!
New multi-launch agreement between Firefly Aerospace and True Anomaly includes three Alpha missions to provide rapid launch capabilities for Tactically Responsive Space mission sets
Cedar Park, Texas, October 17, 2024 – Firefly Aerospace, Inc., an end-to-end space transportation company, and space defense technology company True Anomaly, Inc., today announced a multi-launch agreement for three responsive launch missions aboard Firefly’s Alpha rocket. The first mission will deploy the True Anomaly Jackal Autonomous Orbital Vehicle (AOV) for the U.S. Space Force Space Systems Command’s VICTUS HAZE Tactically Responsive Space (TacRS) mission targeted for 2025. The two additional missions are available for execution between 2025 and 2027.
The Haven-1 project has an ambitious schedule, as its development and preparation for launch are planned to be completed in the second half of 2025. The Vast team includes experienced professionals, particularly former NASA astronaut Andrew Feistel, who provides advice on optimizing the module’s design.
“After three missions to space, we will use our experience to create a comfortable environment on the station. It is important to consider all aspects, from communications and private space to support crew work and scientific progress,” said Andrew Feistel.
Continue reading “ISS will be replaced by a space station with artificial gravity” »
Summary: Researchers have discovered that the protein USP50 regulates DNA replication by managing which enzymes—nucleases or helicases—cleave or unwind DNA strands during replication. This control is crucial for stable replication, especially when the process encounters issues that need restarting. When USP50 is absent, cells struggle to coordinate enzyme use, leading to replication errors and potential genetic instability.
The findings provide new insights into genome maintenance and may help explain some hereditary conditions, such as early-onset aging and certain cancers. Understanding USP50’s role opens doors to potential therapeutic strategies aimed at protecting DNA integrity.
Congresswoman Jennifer Wexton of Virginia, who is retiring after this term, was diagnosed with progressive supranuclear palsy. There is no cure for her condition, which has rapidly robbed her of her mobility, balance and most recently her speech. She’s using her rare diagnosis and AI to help make change during her final months in office.
Fortunately, the past decade has experienced a boom, with over 200 startups bringing novel cancer therapies—primarily antibodies, viruses, or cells—into clinical trials aiming to find alternatives to toxic chemotherapy. Despite these innovations, chemotherapy remains an essential yet toxic part of cancer care. In Pittsburgh, a small team of scientist-entrepreneurs and oncologists started meeting every Friday morning before work, collaborating to search for a new chemistry, one that could replace toxic chemotherapies. Their search soon focused on compelling research about novel ultra-small nanomedicine chemistry that carried potent drugs deep into solid tumors while sparing healthy organs.
This new nanomedicine chemistry fascinated Dr. Sam Rothstein, a scientist-entrepreneur with 20+ years of nanomedicine research experience spanning academia and industry. “We could make a real positive impact on patients,” says Rothstein. “We know that nanomedicines, which keep potent therapies out of healthy organs, improve quality of life. But this novel ultrasmall chemistry could go even further, saving lives by reaching remote cancer cells that current therapies can’t touch.”
Dr. Rothstein set to work building a new company, calling on connections made over a 10+-year career as a life science startup CEO and CSO, where he founded and grew two nanomedicine startups from academic discoveries. After months of market, regulatory, and business research, Duo Oncology was born.
JWST observations of outflows from four young stars reveal in each case a molecular wind with a central cavity surrounding a fast jet. These results point to disk winds driving accretion, with implications for planet formation and evolution.
She’s a real Vincent van Go-bot.
In a first for Sotheby’s, the famed auction house will sell a painting made by a humanoid robot — and it’s expected to fetch up to a whopping $180,000.
Following a concept world premiere in 2022 and a track demo at Le Mans a couple months ago, the Alpine Alpenglow is back, this time serving as a spectacular highlight of the 2024 Paris Motor Show. Alpine has equipped the latest Alpenglow with an all-new “Hy6” twin-turbo V6 engine developed from the ground up to run on hydrogen. The Hy6 doubles the power of the last Alpenglow so the new car not only looks like an extreme track-only supercar, it performs and sounds like one, too.
Alpine originally revealed the Alpenglow at the 2022 Paris Motor Show as a blueprint for its more sustainable sporting future. The concept appeared loosely derived from the extreme styling of the student-crafted A4810 Alpine had shown earlier that year, and came to Paris with the promise of a hydrogen-engine-based drive system of undisclosed size and layout.
The concept continued along as a stunning but mysterious piece of event jewelry right up until this past May, when Alpine officially turned concept car into “rolling laboratory” for a dynamic track debut at the 6 Hours of Spa-Francorchamps and, a month later, Le Mans. Ahead of those demonstration runs, the French automaker finally threw some tender red meat to the starved gearhead masses, confirming a 340-hp 2.0-liter turbo-four hydrogen combustion engine powering the wheels.
I’ve highlighted the top three technologies that I believe will dominate and reshape the e-commerce industry in 2025.
Post written by Gev Balyan, Forbes Councils Member.
